U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer ...
Bristol-Myers Squibb Co is facing a class-action lawsuit related to a $2 billion pension risk transfer deal made five years ...
2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma. 2seventy on ...
Patton Kizzire ended a long victory drought Sunday in the Procore Championship, closing with a scrambling 2-under 70 for a ...
Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure showed that consumer prices continue to ...